Nomination

WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ Date: 21 November 2022 REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L’EUROPE Mr Peep Peterson REGIONALBÜRO FÜR EUROPA Minister of Health and Labour ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО Ministry of Social Affairs Head office: Suur-Ameerika 1 UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark 10129 Tallinn Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01 Estonia Email: [email protected] Website: http://www.euro.who.int Our reference: Your reference: Notre référence: Votre référence: Unser Zeichen: Ihr Zeichen: См. наш номер: На Ваш номер: Dear Sir, WHO Regional Office for Europe Access to Novel Medicines Platform Nomination of focal point At the 72nd session of the WHO Regional Committee for Europe in September 2022, we reached a milestone agreement for the WHO Regional Office for Europe (WHO/Europe) to develop the proposals for establishing a platform to enable multistakeholder collaboration to improve equitable access to effective, novel, high-cost medicines in the WHO European Region. This achievement would not have been possible without the valued support and contributions from our Member States, non-State actors and partner organizations through the Oslo Medicines Initiative (OMI). I want to thank you for your collaboration to date and your trust in WHO/Europe as the honest broker to deliver the platform mandate. It is of vital importance that we have the support, guidance and technical expert advice from our Member States, and we deeply appreciate your participation. In order to operationalize the establishment of this new platform, WHO/Europe will hold a series of consultation meetings with a view to having the governance and terms of reference of the platform proposed for consideration and approval at the 73rd session of the Regional Committee. I have the honour of inviting you to nominate a focal point to participate in this process. Please address your reply – giving the name, functional title and email address of the nominated focal point – at your earliest convenience but no later than 7 December 2022, to Louise Delaney ([email protected]). Following this, we will communicate with the nominated focal point directly and provide them with the necessary documentation, meeting dates and administrative information in due course. It is anticipated that the first discussion with Member States will be held on 12 January 2023, 12:00–14:00 CET. Please save the date. Yours very truly, Dr Hans Henri P. Kluge Regional Director UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email: [email protected] DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int Denmark Copy for information to: Ms Elen Ohov, Adviser, European Union Affairs and International Co-operation Department, Ministry of Social Affairs, Suur-Ameerika 1, 10122 Tallinn, Estonia Ms Triin Uusberg, Head, European Union Affairs and International Co-operation Department, Ministry of Social Affairs, Suur-Ameerika 1, 10129 Tallinn, Estonia H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative, Permanent Mission of the Republic of Estonia to the United Nations Office and other international organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève, Switzerland H.E. Mr William Mart Laanemäe, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia, Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark Ms Kristina Köhler, Liaison Officer, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn, Estonia –2– Saatja: PANAGIOTAKI, Katerina <[email protected]> Saaja: Peep Peterson, Triin Uusberg, Elen Ohov, Elen Ohov, Triin Uusberg, SM Info, Ms K. Saarsalu-Layachi ([email protected]), [email protected], Kaisa.Mitt-Alvarez, [email protected], [email protected], KÖHLER, Kristina, DELANEY, Louise, EURONMP Teema: Reminder: Nomination of focal point for WHO Europe Access to Novel Medicines Platform The Novel Medicines Platform (NMP) Secretariat wishes to send you a gentle reminder that we are looking forward to receiving your nomination of focal point for the upcoming consultation with Member States. If you have any questions about the consultation process or the platform, please feel free to contact us. Thank you for your consideration. The NMP Secretariat [WHO-emblem-ENG-b] From: PANAGIOTAKI, Katerina Sent: Friday, November 25, 2022 10:24 AM To: [email protected]; [email protected]; [email protected] Cc: [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; KÖHLER, Kristina <[email protected]>; DELANEY, Louise <[email protected]>; EURONMP Subject: Nomination of focal point for WHO Europe Access to Novel Medicines Platform Please see the attached correspondence sent from the World Health Organization, Regional Office for Europe. One or more attachements may be included. Veuillez-vous référer à la correspondance ci-jointe du Bureau régional de l'Europe de l'Organisation mondiale de la santé. Une ou plusieurs annexes peuvent être jointes. Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen), Weltgesundheitsorganisation, Regionalbüro für Europa. См. прикрепленное письмо от Европейского регионального бюро Всемирной организации здравоохранения (один или несколько прикрепленных файлов). Sent on behalf of Office of the Regional Director World Health Organization Regional Office for Europe UN CITY, Marmorvej 51, DK-2100 Copenhagen, Denmark Phone +45 4533 7095 / 6788 Web: www.euro.who.int<http://www.euro.who.int/> Follow WHO on Facebook<https://www.facebook.com/WHO>; Twitter<https://twitter.com/WHO>; YouTube<https://www.youtube.com/user/who?sub_confirmation=1>; Instagram<https://www.instagram.com/who/> [WHO-emblem-ENG-b] Saatja: PANAGIOTAKI, Katerina <[email protected]> Saadetud: 25.11.2022 11:23 Adressaat: Peep Peterson <[email protected]>; Triin Uusberg <[email protected]>; Elen Ohov <[email protected]> Koopia: Elen Ohov <[email protected]>; Triin Uusberg <[email protected]>; SM Info <[email protected]>; Ms K. Saarsalu-Layachi <[email protected]>; <[email protected]>; Kaisa.Mitt-Alvarez <[email protected]>; <[email protected]>; <[email protected]>; KÖHLER, Kristina <[email protected]>; DELANEY, Louise <[email protected]>; EURONMP <euro- [email protected]> Teema: Nomination of focal point for WHO Europe Access to Novel Medicines Platform Please see the attached correspondence sent from the World Health Organization, Regional Office for Europe. One or more attachements may be included.Veuillez-vous r¨¦f¨¦rer ¨¤ la correspondance ci-jointe du Bureau r¨¦gional de l'Europe de l'Organisation mondiale de la sant¨¦. Une ou plusieurs annexes peuvent ¨ºtre jointes.Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen), Weltgesundheitsorganisation, Regionalb¨¹ro f¨¹r Europa. §³§Þ. §á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§à§Ö §á§Ú§ã§î§Þ§à §à§ä §¦§Ó§â§à§á§Ö§Û§ã§Ü§à§Ô§à §â§Ö§Ô§Ú§à§ß§Ñ§Ý§î§ß§à§Ô§à §Ò§ð§â§à §£§ã§Ö§Þ§Ú§â§ß§à§Û §à§â§Ô§Ñ§ß§Ú§Ù§Ñ§è§Ú§Ú §Ù§Õ§â§Ñ§Ó§à§à§ç§â§Ñ§ß§Ö§ß§Ú§ñ (§à§Õ§Ú§ß §Ú§Ý§Ú §ß§Ö§ã§Ü§à§Ý§î§Ü§à §á§â§Ú§Ü§â§Ö§á§Ý§Ö§ß§ß§í§ç §æ§Ñ§Û§Ý§à§Ó). Sent on behalf of Office of the Regional Director World Health Organization Regional Office for Europe UN CITY, Marmorvej 51, DK-2100 Copenhagen, Denmark Phone &#43;45 4533 7095 / 6788 Web: Follow WHO on ; ; ;